- Home
- OESX vs INAB Comparison
OESX vs INAB Comparison
Compare OESX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- INAB
- Stock Information
- Founded
- OESX 1996
- INAB 2016
- Country
- OESX United States
- INAB United States
- Employees
- OESX N/A
- INAB N/A
- Industry
- OESX Building Products
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- OESX Consumer Discretionary
- INAB Health Care
- Exchange
- OESX Nasdaq
- INAB Nasdaq
- Market Cap
- OESX 27.6M
- INAB 24.0M
- IPO Year
- OESX 2007
- INAB 2021
- Fundamental
- Price
- OESX $0.78
- INAB $0.27
- Analyst Decision
- OESX Strong Buy
- INAB Strong Buy
- Analyst Count
- OESX 1
- INAB 3
- Target Price
- OESX $3.00
- INAB $7.75
- AVG Volume (30 Days)
- OESX 94.6K
- INAB 836.6K
- Earning Date
- OESX 02-05-2025
- INAB 11-12-2024
- Dividend Yield
- OESX N/A
- INAB N/A
- EPS Growth
- OESX N/A
- INAB N/A
- EPS
- OESX N/A
- INAB N/A
- Revenue
- OESX $91,649,000.00
- INAB N/A
- Revenue This Year
- OESX $11.01
- INAB N/A
- Revenue Next Year
- OESX $17.06
- INAB N/A
- P/E Ratio
- OESX N/A
- INAB N/A
- Revenue Growth
- OESX 14.40
- INAB N/A
- 52 Week Low
- OESX $0.68
- INAB $0.22
- 52 Week High
- OESX $1.53
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- OESX 36.97
- INAB 46.28
- Support Level
- OESX $0.81
- INAB $0.28
- Resistance Level
- OESX $0.85
- INAB $0.26
- Average True Range (ATR)
- OESX 0.03
- INAB 0.03
- MACD
- OESX -0.00
- INAB -0.00
- Stochastic Oscillator
- OESX 11.11
- INAB 30.77
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.